CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Bouvel Investment Partners LLC

Bouvel Investment Partners LLC cut its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 1.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,703 shares of the company’s stock after selling 229 shares during the quarter. Bouvel Investment Partners LLC’s holdings in CRISPR Therapeutics were worth $1,020,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of CRSP. ProShare Advisors LLC increased its holdings in CRISPR Therapeutics by 10.1% during the 1st quarter. ProShare Advisors LLC now owns 5,791 shares of the company’s stock worth $395,000 after purchasing an additional 530 shares during the period. Blair William & Co. IL increased its stake in shares of CRISPR Therapeutics by 8.2% during the first quarter. Blair William & Co. IL now owns 147,890 shares of the company’s stock worth $10,080,000 after buying an additional 11,190 shares during the period. Vanguard Group Inc. raised its holdings in CRISPR Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock valued at $111,564,000 after acquiring an additional 46,148 shares in the last quarter. Orion Capital Management LLC lifted its stake in CRISPR Therapeutics by 44.0% in the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock worth $49,000 after acquiring an additional 220 shares during the last quarter. Finally, SR One Capital Management LP purchased a new position in CRISPR Therapeutics in the first quarter worth approximately $71,496,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CRSP shares. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Rodman & Renshaw assumed coverage on CRISPR Therapeutics in a research report on Friday, August 2nd. They set a “buy” rating and a $90.00 target price on the stock. Truist Financial lowered their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $74.94.

CRISPR Therapeutics Price Performance

NASDAQ CRSP opened at $49.79 on Thursday. The business has a 50 day moving average price of $47.80 and a 200 day moving average price of $52.12. The company has a market capitalization of $4.25 billion, a P/E ratio of -17.59 and a beta of 1.67. CRISPR Therapeutics AG has a 1-year low of $43.42 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the previous year, the company posted ($1.41) EPS. On average, research analysts expect that CRISPR Therapeutics AG will post -5.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the sale, the chief executive officer now directly owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the sale, the chief executive officer now owns 196,540 shares in the company, valued at $10,931,554.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,382 shares of company stock worth $1,917,679. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.